Pamela Munster, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Pamela Munster, MD

Professor, Department of Medicine (Hematology/Oncology), UCSF; Director, Early Phase Clinical Trials Unit and Leader, Developmental Therapeutics Program, UCSF Helen Diller Family Comprehensive Cancer Center

Phone: (415) 353-7070 (appts)
Box 1711, UCSF
San Francisco, CA 94143-1711

UCSF Profiles | Physician Referral Directory | Lab Website

Cancer Center Membership

Program Member » Breast Oncology» Developmental Therapeutics

Research Summary

My clinical research interests are first-in-human early phase clinical trials of novel compounds and alternative strategies for the treatment and prevention of cancer. I have been involved in clinical and translational research in early phase clinical trials since 1998. As the program leader for Development Therapeutics and the PI of a peer-reviewed basic science lab, my main focus is on translating preclinical findings into early-stage clinical trials with extensive PK and integration of PD correlative studies and molecular imaging for patients with advanced stage cancer.

My basic research interest is centered on the role of epigenetic modification in therapy resistance in breast cancer and epigenetic priming. In addition to studying basic mechanisms of hormone therapy resistance, we have shown that epigenetic modification plays a crucial role in the hormonal regulation and carcinogenesis of breast cancer.

Education

Kantonsschule Sargans, Switzerland, Baccalaureate, 1983, Sciences, Liberal Arts
University of Bern Switzerland, Doctorate, 1990, Medicine
University of Bern Switzerland, MD Thesis, 1992, Medicine


Professional Experience

  • 1990-1992
    University of Bern, Department of Physiology, Teaching Assignment in Physiology
  • 1992-1993
    Indiana University at Indianapolis, Krannert Institute of Cardiology
  • 1993-1996
    Residency in Internal Medicine Indiana University Medical Center at Indianapolis
  • 1996-1999
    Hematology-Oncology Fellowship at Memorial Sloan Kettering Cancer Center/The New York Hospital-Cornell Medical Center New York
  • 1999-2000
    Research Associate, Department of Medicine, Breast Program, Memorial Sloan Kettering Cancer Center, New York
  • 2000-2001
    Clinical Assistant Member, Memorial Sloan Kettering Cancer Center, Department of Medicine, Breast Cancer Service
  • 2001-2006
    Assistant Professor: Division of Breast Oncology & Experimental Therapeutics, Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center & Research Institute; Division of Medical Oncology & Hematology, Dept of Internal Medicine, University of South Florida
  • 2006-2008
    Associate Professor: Division of Breast Oncology & Experimental Therapeutics, Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center & Research Institute; Division of Medical Oncology & Hematology, Dept of Internal Medicine, University of South Florida
  • 2007-present
    Faculty Affiliate, Colorade State University, Ft. Collins, CO
  • 2008-2010
    Associate Professor in Residence, Department of Medicine, Division of Hematology/Oncology, UCSF
  • 2008-present
    Director, Early Phase Clinical Trials Program and Associate Director, Investigational Therapeutics, UCSF Helen Diller Family Comprehensive Cancer Center
  • 2010-present
    Professor in Residence, Department of Medicine, Division of Hematology/Oncology, UCSF

Honors & Awards

  • 1998
    John Mendelsohn House staff Teaching Award
  • 1999
    AACR-AFLAC Young Investigators Scholar Award 1999
  • 2000, 2001
    Byrne Fund Award
  • 2003-2005
    Don Shula Career Development Award, 2003-2005
  • 2007-2008
    Greatest Number of Investigator-Initiated Trials Written & Implemented, H. Lee Moffitt Cancer Center & Research Institute
  • 2008
    Research Highlights, Department of Defense, Congressionally Directed Medical Research Programs

Selected Publications

  1. Ferrarotto R, Mitani Y, Diao L, Guijarro I, Wang J, Zweidler-McKay P, Bell D, William WN, Glisson BS, Wick MJ, Kapoun AM, Patnaik A, Eckhardt G, Munster P, Faoro L, Dupont J, Lee JJ, Futreal A, El-Naggar AK, Heymach JV. Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors. J Clin Oncol. 2016 Nov 21; JCO2016675264.
    View on PubMed
  2. Sarantopoulos J, Goel S, Chung V, Munster P, Pant S, Patel MR, Infante J, Tawbi H, Becerra C, Bruce J, Kabbinavar F, Lockhart AC, Tan E, Yang S, Carlson G, Scott JW, Sharma S. Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016 Nov; 78(5):921-927.
    View on PubMed
  3. Munster PN. Effect of Temporary Ovarian Suppression on Chemotherapy-Induced Amenorrhea, Pregnancy, and Outcome. JAMA Oncol. 2016 Aug 1; 2(8):1089-90.
    View on PubMed
  4. Terranova-Barberio M, Thomas S, Munster PN. Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors. Immunotherapy. 2016 Jun; 8(6):705-19.
    View on PubMed
  5. Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, Van't Veer L, Yau C, Wolf DM, Munster PN. A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. Breast Cancer Res Treat. 2016 Feb; 155(3):521-30.
    View on PubMed
  6. Rodriguez-Wallberg K, Turan V, Munster P, Oktay K. Can ovarian suppression with gonadotropin-releasing hormone analogs (GnRHa) preserve fertility in cancer patients? Ann Oncol. 2016 Feb; 27(2):257.
    View on PubMed
  7. Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, Agarwal N, Kleha JF, Durante M, Adams L, Smith DA, Lampkin TA, Morris SR, Kurzrock R. First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clin Cancer Res. 2016 Apr 15; 22(8):1932-9.
    View on PubMed
  8. Chien AJ, Duralde E, Hwang R, Tsung K, Kao CN, Rugo HS, Melisko ME, Esserman LJ, Munster PN, Cedars M, Kerlikowske K, McCulloch CE, Rosen MP. Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer. Breast Cancer Res Treat. 2015 Aug; 153(1):173-81.
    View on PubMed
  9. Piha-Paul SA, Munster PN, Hollebecque A, Argilés G, Dajani O, Cheng JD, Wang R, Swift A, Tosolini A, Gupta S. Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours. Eur J Cancer. 2015 Sep; 51(14):1865-73.
    View on PubMed
  10. Gupta S, Argilés G, Munster PN, Hollebecque A, Dajani O, Cheng JD, Wang R, Swift A, Tosolini A, Piha-Paul SA. A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies. Clin Cancer Res. 2015 Dec 1; 21(23):5235-44.
    View on PubMed
  11. Munster PN. More Options for Fertility Preservation for Patients With Cancer. J Clin Oncol. 2015 Aug 1; 33(22):2413-5.
    View on PubMed
  12. Oktay K, Rodriguez-Wallberg K, Munster P. Ovarian protection during adjuvant chemotherapy. N Engl J Med. 2015 Jun 4; 372(23):2268-9.
    View on PubMed
  13. Raha P, Thomas S, Thurn KT, Park J, Munster PN. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression. Breast Cancer Res. 2015; 17:26.
    View on PubMed
  14. Daud AI, Ashworth MT, Strosberg J, Goldman JW, Mendelson D, Springett G, Venook AP, Loechner S, Rosen LS, Shanahan F, Parry D, Shumway S, Grabowsky JA, Freshwater T, Sorge C, Kang SP, Isaacs R, Munster PN. Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. J Clin Oncol. 2015 Mar 20; 33(9):1060-6.
    View on PubMed
  15. Park J, Thomas S, Munster PN. Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy. Epigenomics. 2015; 7(4):641-52.
    View on PubMed
  16. Aggarwal R, Grabowsky J, Strait N, Cockerill A, Munster P. Impact of patient ethnicity on the metabolic and immunologic effects of PI3K-mTOR pathway inhibition in patients with solid tumor malignancies. Cancer Chemother Pharmacol. 2014 Aug; 74(2):359-65.
    View on PubMed
  17. Zhang X, Munster PN. New protein kinase inhibitors in breast cancer: afatinib and neratinib. Expert Opin Pharmacother. 2014 Jun; 15(9):1277-88.
    View on PubMed
  18. Chien AJ, Munster PN, Melisko ME, Rugo HS, Park JW, Goga A, Auerback G, Khanafshar E, Ordovas K, Koch KM, Moasser MM. Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. J Clin Oncol. 2014 May 10; 32(14):1472-9.
    View on PubMed
  19. Mahadevan D, Sutton GR, Arteta-Bulos R, Bowden CJ, Miller PJ, Swart RE, Walker MS, Haluska P, Munster PN, Marshall J, Hamid O, Kurzrock R. Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies. Cancer Chemother Pharmacol. 2014 Mar; 73(3):467-73.
    View on PubMed
  20. Kadoch C, Li J, Wong VS, Chen L, Cha S, Munster P, Lowell CA, Shuman MA, Rubenstein JL. Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma. Clin Cancer Res. 2014 Feb 15; 20(4):1029-41.
    View on PubMed

Go to UCSF Profiles, powered by CTSI